Calliditas Therapeutics: Interim Report Q2, 2022 ...Middle East

PR Newswire - News
STOCKHOLM, Aug. 18, 2022 /PRNewswire/ -- European approval for Kinpeygo® "On May 19th, the European Medicines Agency (EMA) announced that it had adopted a positive opinion regarding the application for conditional approval of Kinpeygo® for the treatment of IgA nephropathy, and on July...

Hence then, the article about calliditas therapeutics interim report q2 2022 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Calliditas Therapeutics: Interim Report Q2, 2022 )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News